Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

Yasuhiko Yamamoto,1,2 Ichiro Kato,2 Toshio Doi,3 Hideto Yonekura,1 Seiji Ohashi,3 Masayoshi Takeuchi,4 Takuo Watanabe,1,5 Sho-ichi Yamagishi,1 Shigeru Sakurai,1 Shin Takasawa,2 Hiroshi Okamoto,2 and Hiroshi Yamamoto1

1Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
2Department of Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan
3Department of Laboratory Medicine, Tokushima University School of Medicine, Tokushima, Japan
4Department of Biochemistry, Faculty of Pharmaceutical Science, Hokuriku University, Kanazawa, Japan
5Department of Stem Cell Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

Address correspondence to: Hiroshi Yamamoto, Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan.
Phone: 81-76-265-2180; Fax: 81-76-234-4226; E-mail: yamamoto@med.kanazawa-u.ac.jp.

Received for publication November 13, 2000, and accepted in revised form May 29, 2001.

Vascular complications arising from multiple environmental and genetic factors are responsible for many of the disabilities and short life expectancy associated with diabetes mellitus. Here we provide the first direct in vivo evidence that interactions between advanced glycation end products (AGEs; nonenzymatically glycosylated protein derivatives formed during prolonged hyperglycemic exposure) and their receptor, RAGE, lead to diabetic vascular derangement. We created transgenic mice that overexpress human RAGE in vascular cells and crossed them with another transgenic line that develops insulin-dependent diabetes shortly after birth. The resultant double transgenic mice exhibited increased hemoglobin A1c and serum AGE levels, as did the diabetic controls. The double transgenic mice demonstrated enlargement of the kidney, glomerular hypertrophy, increased albuminuria, mesangial expansion, advanced glomerulosclerosis, and increased serum creatinine compared with diabetic littermates lacking the RAGE transgene. To our knowledge, the development of this double transgenic mouse provides the first animal model that exhibits the renal changes seen in humans. Furthermore, the phenotypes of advanced diabetic nephropathy were prevented by administering an AGE inhibitor, (±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195), thus establishing the AGE-RAGE system as a promising target for overcoming this aspect of diabetic pathogenesis.


Introduction

Nephropathy is a life-threatening complication of diabetes mellitus and is the leading cause of end-stage renal disease (ESRD) in developed countries (1). Approximately 30% of insulin-dependent diabetes mellitus (IDDM) patients suffer from diabetic nephropathy (1, 2), eventually undergoing renal dialysis or transplantation. The features characteristic of this disease include persistent albuminuria, a progressive decline in renal function, and, histopathologically, mesangial expansion followed by glomerulosclerosis. To understand the pathogenesis of diabetic nephropathy and to develop preventive and therapeutic measures against it, suitable animal models are needed. However, there has been no single animal model that develops the renal changes seen in humans (3). Spontaneously diabetic animals such as nonobese diabetic (NOD) mice develop only limited lesions, this being, at most, mild mesangial sclerosis (4). The same is the case with chemically induced diabetic rodents (5).

Exposure of proteins to reducing sugars like glucose results in nonenzymatic glycation, which forms reversible Schiff bases and Amadori compounds (6). A series of further complex molecular rearrangements then yields irreversible advanced glycation end products (AGEs) (6). In diabetes, prolonged hyperglycemia superdrives this reaction and AGEs accumulate in the circulating blood and in various tissues (6). AGE infusion studies in experimental animals have suggested a potential role of AGEs in the pathogenesis of diabetic nephropathy (7, 8) as well as retinopathy (9). Receptor-dependent mechanisms are likely to work in the AGE-induced tissue dysfunction. Receptor for AGE (RAGE) is the best-characterized cell surface molecule to which AGEs bind, and it has been shown to be expressed in a variety of cell types (10–15). Recent in vitro studies demonstrated that AGEs elicit vascular cell changes typical of diabetes. These include angiogenic and thrombogenic responses of endothelial cells (ECs) (12, 13), a decrease in pericytes, (14) and the enhanced synthesis of ECM proteins by
double transgenic animals developed renal insufficiency and advanced glomerulosclerosis that resembled human diabetic nephropathy. This in vivo approach has thus established the functional importance of the AGE-RAGE system in the development of diabetic nephropathy, and the RAGE-overexpressing IDDM mice are regarded as the first single animal model in which the process of diabetes-induced kidney changes leading to ESRD can be followed. The AGE-RAGE system would seem to be a promising target for the prophylaxis and therapy of diabetic complications, and a study with (+)-2-isopropylidenhydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) (17) included in this paper suggests that the inhibition of AGE formation could be an effective remedy.

Methods

Construction of transgenic mice and induction of diabetes. A mouse flk-1 promoter previously reported to be active in vascular ECs in vitro was used (18). The 0.9-kbp fragments of the mouse flk-1 promoter and the 3.4-kbp fragments of the entire exonic and intronic region of the human RAGE gene (provided by T. Ikemura and K. Sugaya, National Institute of Genetics, Mishima, Japan) were ligated in the correct orientation by a modified polymerase chain reaction method (19). Primers used in the PCR reactions were 5′-GAGGTACCCATCCACCGAAGTGTCTTCTGGGA-3′ and 5′-CTGCTTTTTCCGGCTGCATCTGCCCATCGCCGC-TGGGCA-3′ (nucleotides –623 to –597, +280 to +299) for mouse flk-1 (18), and 5′-ATGGCCGAGCGACAGCAGTCTTCC-3′ and 5′-GAGGCCCGGTCACTTCTCACCCATTGG-AAGTTGCTTTCCGGCTGCATCTGCCCATCGCCGC-TGGGCA-3′ (nucleotides 6665–6685, 10027–10049) for human RAGE gene (20), containing KpnI and NotI sites (underlined sequences), respectively. The resultant 4.3-kbp hybrid gene was microinjected into fertilized eggs as described (16). Six out of 24 newborn offspring carrying the transgene, as detected by PCR analyses of DNA from tail tissue using primers for flk-1 promoter (5′-AGGGACGGAGAAGGAGT-3′+240 to +256) (18) and human RAGE gene (5′-TCACCCCCACGACTGAG-3′: 6704–6720) (20).

RAGETg was crossbred with another transgenic mouse carrying human cDNA for inducible nitric oxide synthase (iNOS) under the control of the insulin promoter (iNOS-Tg) (16). There was no expression of iNOS protein in the kidney (16). The resultant four groups of male littermates were used for analysis after PCR verification of the transgenes. Each group was fed either normal or 0.28% OPB-9195 mixed mouse chow (provided by Fujii Memorial Research Institute, Otsuka Pharmaceutical, Ohtsu, Japan) from 1 to 6 months after birth. The levels of blood glucose and hemoglobin A1c (HbA1c) were measured from tail vein blood using Dexter Z sensor and DCA2000 analyzer (Bayer Medical, Tokyo, Japan) (21), respectively.

The procedures were approved by the Institutional Animal Care and Use Committee guidelines at Tohoku University and at Kanazawa University Graduate School of Medical Science.

---

Figure 1

Generation and characterization of RAGE transgenic mice. (a) Transgene construct. The human RAGE genomic sequence, beginning with the initiator codon in exon 1 and ending 129 bp downstream from the last exon, was placed under the transcriptional control of the murine flk-1 promoter. The flk-1 fragment encompassed the 5′ untranslated region (dark gray box), sharing the ATG codon in the RAGE fragment. (b) Transgene-derived transcripts. Total RNAs isolated from various tissues of line 102 and 103 heterozygotes were analyzed by RT-PCR. The granulation tissue — the focus of angiogenesis — was prepared by punching out an area of the dorsal skin about 4–5 mm in diameter. The PCR-amplified products had a chain length of 354 bp as predicted and were sequence-verified. (c) Immunofluorescence staining of kidneys from line 102 RAGETg or nontransgenic control at 4 months of age using anti-human RAGE-specific polyclonal Ab. Original magnification, ×430. (d) Translation products of the transgene. Extracts of isolated ECs from renal cortex or peripheral blood monocytes of line 102 RAGETg or nontransgenic control were immunodetected with the human RAGE Ab. Specific bands were marked at 55 kDa in line 102 RAGETg EC and monocyte extracts. VE-cad, VE-cadherin, i.e., an EC marker; CD14, a monocyte marker.

renal mesangial cells (15). All of these changes are RAGE-dependent, as evidenced by their cessation by RAGE antisense or ribozyme (12–15).

In the present study, we constructed transgenic mice that overexpress human RAGE in vascular cells (RAGETg). When these mice were made diabetic by crossbreeding with another transgenic mouse deficient in the islet production of insulin (16), the resultant
RT-PCR. Total RNA was isolated from various tissues, and from isolated renal glomeruli, of transgenic or control mice using the guanidinium thiocyanate method, and reverse-transcribed (22). The isolation of glomeruli from mouse kidneys was performed as described (23). Primer sequences for human RAGE mRNA detection were 5′-AACGGCCCTGTTGCTAATGAG-3′ and 5′-CACCCATTGGACCTCCTCCA-3′ (nucleotides 508–528 and 728–747 in GenBank AB036432); those for mouse RAGE mRNA detection were 5′-CCTGGGTGCTG-3′ and 5′-GATCTGGGTGCTCTTACG-3′ (nucleotides 31–52 and 1209–1230 in GenBank L33412); those for mouse GAPDH mRNA detection were the same as described (24). The amounts of total RNA templates (100 ng) and the numbers for amplification cycles (35 cycles for human RAGE and 30 cycles for mouse RAGE and GAPDH) were chosen in quantitative ranges. An aliquot of each RT-PCR product was electrophoresed on 2% agarose gel containing ethidium bromide.

Isolation of ECs and monocytes, and Western blot analysis. ECs from mouse renal cortex were cultivated for 2 days in a gelatin-coated plate after isolation by specific selection with rat anti-mouse CD31/PECAM-1 mAb–coated (MEC7.46; HyCult Biotechnology b.v.) magnetic beads (Dynabeads M-450 sheep anti-rat IgG; Dynal, Oslo, Norway) as described (25). Monocytes were isolated from peripheral blood by Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden) centrifugation followed by magnetic cell sorter (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) using CD11b/Mac-1 mAb–coated MicroBeads (Miltenyi Biotec) according to the manufacturer’s instructions (26). Cells were homogenized in PBS, 1% NP-40, 0.5% deoxycholate, 10 mM EDTA, 0.1% SDS, and 1.0 mM PMSF, and centrifuged at 15,000 g for 30 minutes at 4°C. Supernatants were used for protein assay. Protein concentrations were determined using Coomassie Protein Assay Reagents (Pierce Chemical Co., Rockford, Illinois, USA) by the method of Bradford (27). Proteins were electrophoresed on 10% SDS-PAGE and transferred electrophoretically to polyvinylidene difluoride membranes. Membranes were blocked with 5% nonfat dry milk in PBS and 0.1% Tween-20, and then incubated with 1:100 dilution of goat anti–vascular endothelial-cadherin (anti–VE-cadherin) polyclonal Ab, and anti–vascular endothelial-cadherin (anti–VE-cadherin) polyclonal Ab (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), 1:100 dilution of goat anti-mouse CD14 polyclonal Ab (Santa Cruz Biotechnology Inc.), or 0.25 µg/ml of immunoaffinity-purified anti-RAGE polyclonal Ab raised against 16-amino-acid synthetic peptides (QRRQRGGERKAPENQ) that corresponded to amino acid residues 364–379 of the human RAGE protein (11). After incubation with 1:2,000 dilution of anti-goat or anti-rabbit IgG conjugated to horseradish peroxidase, the immune complexes were visualized with an enhanced chemiluminescence detection system (ECL; Amersham Pharmacia Biotech, Piscataway, New Jersey, USA).

Determination of AGE concentration. Serum Nε-carboxymethyl-lysine (CML) and non-CML AGEs were differentially determined using a competitive ELISA as described (28). One U/ml of CML or non-CML AGEs corresponded to a protein concentration of 1 µg/ml CML-BSA or non-CML AGE-BSA, respectively.

Determination of urine albumin/creatinine ratio and serum creatinine. Urinary or serum creatinine was measured by the Jaffe reaction (29). The level of urinary albumin was measured by ELISA with sheep anti-mouse albumin as described (4, 30). The ratio of urinary albumin to creatinine was then calculated.

Renal histology and morphometric analyses. Kidneys were processed for light microscopy examination, and the severity of the renal sclerosis was scored by multiple analysts on an arbitrary scale from 0 to 4 (4, 31, 32). The mean glomerular volume was determined as described previously (4, 30). To quantify mesangial expansion, periodic acid-Schiff–positive (PAS-positive) area in the mesangium was determined as mesangium area using an image analyzer with a microscope (Image Processor for Analytical Pathology; Sumitomo Chemical Co., Tokyo, Japan) (33). Immunofluorescence analysis was carried out as described (30, 34) using an affinity-purified polyclonal Ab specific to human RAGE raised against 10-amino-acid synthetic peptides (PLVP-NEKGVS) corresponding to amino acid residues 163–172 of the human RAGE protein (11), anti-CML Ab, and anti–non-CML AGE Ab (28).

Results

Expression of RAGE transgene. We created RAGETg by introducing into fertilized ova of C57BL/6J × CBA/J F1 mice a transgene carrying human RAGE genomic DNA under the control of the murine flk-1 promoter, which...
acts in ECs (18) (Figure 1a). PCR analysis revealed that five out of six potentially transgenic mice exhibited transgene transmission into their germlines. Two independent lines, 102 and 103, carrying high copy numbers, were used for subsequent experiments. RT-PCR analysis with human RAGE-specific primers revealed active transcription of the transgene in the lung, skin granulation tissue (the focus of angiogenesis), kidney, heart, aorta, and eyes of each line, but not in controls (Figure 1b). Immunofluorescent examination of kidney sections demonstrated that glomeruli of RAGETg were positively stained for human RAGE in an EC pattern, but not in controls (Figure 1c). Immunoblotting of cell extracts from renal cortical ECs demonstrated the overexpression of RAGE proteins in RAGETg (Figure 1d). Expression of the RAGE protein was also detected in monocytes from peripheral blood of RAGETg (Figure 1d).

**Induction of diabetes.** There are several means to induce diabetes in experimental animals (35, 36). Chemical or surgical maneuvers for diabetes induction might, however, cause some diversity among individual animals in terms of the extent of severity and the onset of diabetes. Accordingly, we employed a genetic approach by which a diabetic state and advanced glycation as well would be most stably induced. That is, RAGETg was crossbred with iNOSg that consistently develops IDDM as early as 1 week after birth due to the iNOS-mediated selective destruction of insulin-producing pancreatic β cells (16). RAGETg was back-crossed to the nontransgenic parental strain CD-1 of iNOSg for 4 or 5 generations to unify the genetic background. Then, the heterozygotes of male iNOSg and female RAGETg were mated, thereby yielding four groups of littermates at five or six generations with CD-1 background, which carried both, either, or neither of the transgenes. They were tentatively designated DM’RAGETg’, DM’RAGETg’, DM’RAGETg’, and DM’RAGETg’, since the mice carrying the iNOS transgene exclusively developed hyperglycemia regardless of the presence or absence of the RAGE transgene. Blood analysis revealed sustained hyperglycemia and high HbA1c levels in the former two groups but not in the latter two (Table 1). There were no significant differences in these indices between DM’RAGETg’ and DM’RAGETg’ (Table 1). Body weight was also invariant between the two groups at all time points tested during the 6-month observation period (data not shown). To determine the levels of circulating AGEs, serum was differentially measured by competitive ELISA for CML (derivative of AGEs mainly formed by peroxidation) and for non-CML AGEs (28). Serum non-CML AGE levels rapidly increased with time in both DM’RAGETg’ and DM’RAGETg’ mice, but without significant differences between them at each time point (Table 1). There was a tendency of higher serum CML levels in the diabetic groups than in the nondiabetic groups, but without significant differences (Table 1). These findings were comparable to observations in human diabetic and nondiabetic subjects (28). With the 103 line, similar results were obtained by blood glucose, HbA1c, and serum AGE assays (data not shown).

**Phenotypic changes of the kidney.** The kidney weight/body weight ratios from DM’RAGETg’ showed a marked increase when compared with age-matched DM’RAGETg’ mice (Figure 2a). The urinary albumin/creatinine ratio became significantly higher in DM’RAGETg’ than in the other groups at 4 months (Figure 2b). The microscopic lesions noted in the diabetic groups consisted of glomerular cell proliferation, glomerular hypertrophy, mesangial expansion, and glomerulosclerosis. DM’RAGETg’ showed accelerated increases in glomerular cell proliferation and glomeru-
lar volume in comparison with DM+RAGETg– mice (Figure 3). Diffuse glomerulosclerosis progressed as the mice aged in both groups. However, there was a conspicuous difference in the severity of mesangial expansion and glomerulosclerosis at 4 months between DM+RAGETg+ and DM+RAGETg–, as evidenced by increased accumulation of PAS-positive materials in the mesangial area of the former (Figure 4, a–d). Quantitative examinations of at least 50 glomeruli per mouse revealed significant increases in mesangium area, mesangium fraction (relative mesangium area calculated as mesangium area/glomerular area ratio) (Figure 5), and sclerosis index in DM’RAGETg’ compared with DM’RAGETg’ mice at 4 months of age (Figure 6a). Immunostaining showed that significant amounts of not only non-CML AGEs but also CML accumulated in the mesangial area in the diabetic mice, but not in nondiabetic mice (Figure 7, a–d). At 6 months of age, the serum creatinine level of DM+RAGETg+ increased to 1.24 ± 0.07 mg/dl, being the highest among the groups (Figure 6a). Further, typical nodular lesions and hyaline arteriosclerosis were noted at 8 months of age in DM+RAGETg+ (Figure 4e). Since hypertension has been known to be another risk factor for progressive glomerular disease (37), the blood pressure was monitored. Though DM’RAGETg’ showed a slightly higher value at 6 months of age, there was no statistically significant difference in systolic blood pressure among the four groups (DM’RAGETg’, 135 ± 8 mmHg; DM’RAGETg’, 108 ± 10 mmHg; DM’RAGETg’, 109 ± 9 mmHg; DM’RAGETg’, 108 ± 10 mmHg). Experiments with the line 103 series revealed a similar tendency in all of the above indices.

Upregulation of endogenous mouse RAGE mRNA in diabetes. Since AGE ligands themselves have been shown to induce the transcription of the RAGE gene (38), we determined the endogenous mouse RAGE mRNA levels along with the transgene-derived human RAGE mRNA levels in renal glomeruli by RT-PCR with mouse- or human-specific primer pairs. The endogenous RAGE mRNA levels were increased in glomeruli of DM+RAGETg+ since 2 months of age and in DM+RAGETg– too at 4 months of age (Figure 7e). On the other hand, the transgene expression under the control of flk-1 promoter was invariant under diabetic conditions (Figure 7e).

Suppression of diabetic nephropathy by OPB-9195. We then conducted an intervention study with OPB-9195, a thiazolidine derivative that can inhibit AGE formation by blocking carbonyl groups on glycation intermediates (17). When the mice had received OPB-9195 orally for 5 months, the serum non-CML and CML AGE levels of both DM+RAGETg+ and DM+RAGETg– were significantly reduced to levels similar to those of nondiabetic mice, with blood glucose and HbA1c being essentially unaffected (Table 1). The OPB-9195 treatment signifi-

### Table 1

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (mo)</th>
<th>Mice (n)</th>
<th>Blood glucose (mg/dl)</th>
<th>HbA1c (%)</th>
<th>CML (U/ml)</th>
<th>Non-CML AGES (U/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM’RAGETg’</td>
<td>2</td>
<td>4</td>
<td>509 ± 61</td>
<td>8.0 ± 0.6</td>
<td>4.1 ± 0.4</td>
<td>10.3 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>3</td>
<td>609 ± 94</td>
<td>9.5 ± 0.1</td>
<td>3.7 ± 0.6</td>
<td>11.9 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>7</td>
<td>547 ± 13</td>
<td>8.3 ± 0.6</td>
<td>7.7 ± 0.1</td>
<td>24.2 ± 1.3</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>8</td>
<td>693 ± 26</td>
<td>9.4 ± 0.5</td>
<td>5.4 ± 0.4</td>
<td>14.2 ± 0.8</td>
</tr>
<tr>
<td>DM’RAGETg’</td>
<td>2</td>
<td>6</td>
<td>482 ± 22</td>
<td>8.2 ± 0.4</td>
<td>3.4 ± 0.5</td>
<td>7.3 ± 2.3</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>5</td>
<td>447 ± 45</td>
<td>9.1 ± 0.5</td>
<td>5.1 ± 0.8</td>
<td>14.4 ± 2.5</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>9</td>
<td>503 ± 19</td>
<td>7.5 ± 0.8</td>
<td>7.3 ± 0.6</td>
<td>20.7 ± 2.5</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>5</td>
<td>586 ± 74</td>
<td>8.9 ± 0.9</td>
<td>4.3 ± 1.0</td>
<td>10.2 ± 2.6</td>
</tr>
<tr>
<td>DM’RAGETg’</td>
<td>2</td>
<td>6</td>
<td>177 ± 5</td>
<td>3.2 ± 0.2</td>
<td>2.9 ± 0.6</td>
<td>2.5 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>6</td>
<td>157 ± 3</td>
<td>3.8 ± 0.3</td>
<td>3.3 ± 0.6</td>
<td>6.4 ± 1.6</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>11</td>
<td>134 ± 4</td>
<td>&lt;2.5</td>
<td>7.6 ± 0.3</td>
<td>20.2 ± 1.7</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>4</td>
<td>145 ± 16</td>
<td>&lt;2.5</td>
<td>6.3 ± 1.0</td>
<td>13.2 ± 3.7</td>
</tr>
<tr>
<td>DM’RAGETg’</td>
<td>2</td>
<td>3</td>
<td>188 ± 8</td>
<td>3.3 ± 0.1</td>
<td>2.6 ± 1.0</td>
<td>2.8 ± 0.6</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>5</td>
<td>157 ± 4</td>
<td>3.4 ± 0.1</td>
<td>3.0 ± 0.1</td>
<td>4.4 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>11</td>
<td>125 ± 5</td>
<td>&lt;2.5</td>
<td>6.2 ± 0.4</td>
<td>12.6 ± 1.0</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>10</td>
<td>169 ± 9</td>
<td>&lt;2.5</td>
<td>5.0 ± 0.7</td>
<td>8.7 ± 1.1</td>
</tr>
</tbody>
</table>

Data are expressed as the mean ± SEM. OPB, oral OPB-9195 administration for 5 months. *P < 0.002 and **P < 0.05 compared with CML values of DM’RAGETg’ and DM’RAGETg’ at 6 months of age without OPB-9195 treatment, respectively. *P < 0.002 and **P < 0.05 compared with non-CML AGE values of DM’RAGETg’ and DM’RAGETg’ at 6 months of age without OPB-9195 treatment, respectively. Statistical analysis was performed by t test. A high non-CML AGE level was noted in DM RAGETg’ at 6 months; the reason for this may be partly explained by hemolysis.

**Figure 5**
Mesangial expansion. Mesangium area (left) and mesangium fraction (right). Numbers on columns indicate months of age. Data are mean ± SEM. *P < 0.05. Statistical analysis was performed by t test.
cantly suppressed the increases in the kidney weight/body weight ratio (Figure 6b) and the sclerosis index and serum creatinine (Figure 6a) of DM+RAGETg+ at 6 months of age. A similar tendency was observed in experiments with the line 103 series (data not shown).

Discussion
In its early phase, diabetic nephropathy is characterized by increased albuminuria, glomerular hypertrophy, and nephromegaly (37). Mesangial expansion, glomerulosclerosis, and increased serum creatinine then follow in the late phase (37). In this study, the diabetic mouse itself, which we used to mate with the RAGETg, showed glomerular hypertrophy until 4 months of age and progressive mesangial expansion and glomerulosclerosis afterward. Furthermore, overexpression of human RAGE gene in ECs, which normally were only faintly stained for RAGE protein in renal arteries, arterioles, and glomerular capillaries (39–41), was found to result in a significant acceleration of all of the early- and late-phase indices of diabetic nephropathy. Because the extent of this acceleration was roughly proportional to the degree of RAGE transgene expression, and because circulating levels of AGEs and their deposition in renal glomeruli were essentially invariant between the IDDM animals carrying or not carrying the RAGE transgene, it was considered to be the level of RAGE expression that had rate-limited the progression of diabetic nephropathy. The higher expression of RAGE induced the earlier and higher expression of endogenous mouse RAGE in renal glomeruli under diabetic conditions (Figure 7e). The upregulation of the endogenous RAGE would then superdrive the development of the renal lesions in DM+RAGETg+.

Figure 6
(a) Sclerosis index and serum creatinine level. (b) Kidney weight/body weight ratio. Open bars, animals not treated with OPB-9195; filled columns, animals treated with OPB-9195. Numbers on columns indicate months of age. Data are mean ± SEM. *P < 0.05, †P < 0.005, ‡P < 0.001. Statistical analysis was performed by t test.

Figure 7
Stain for non-CML AGEs (a and b) and CML (c and d) in the kidneys from 4-month-old line 102 DM+RAGETg+ (a and c) and DM+RAGETg- (b and d) mice. Glomeruli were stained for non-CML AGEs and CML in DM+RAGETg+ to extents similar to those in DM+RAGETg- but were much less stained in DM- RAGETg+ and DM- RAGETg- mice. Original magnification, ×330. (e) Upregulation of mouse RAGE mRNA in diabetic glomeruli. Total RNAs isolated from glomeruli of each of the four groups in line 102 were analyzed by RT-PCR. mRAGE, mouse RAGE mRNA; hRAGE, human RAGE mRNA. Numbers indicate months of age.
azolidine compound, OPB-9195, significantly suppressed the development of the renal insufficiency, nephromegaly, and glomerulosclerosis in DM RAGETg+ without affecting the levels of blood glucose or HbA1c. OPB-9195 is known to inactivate carbonyl intermediates of nonenzymatic glycation with an activity about one order of magnitude more potent than that of aminoguanidine (17). The prevention of diabetic nephropathy by OPB-9195 in the transgenic mice was associated with a decrease in AGES, though this could reflect other hitherto unknown properties of the drug. These results indicate that endothelial RAGE and its engagement by AGES contribute to the full expression of diabetic nephropathy, and that the AGE-RAGE system could become a target for intervention in this disease.

Then, how does the AGE-RAGE interaction lead to such kidney changes? It is reported that AGE-RAGE interactions upregulate the production of various cytokines and growth factors such as TNF-α (42), PDGF (22), and VEGF (12) via oxidant stress formation. TNF-α and VEGF are known to increase vascular permeability and to diminish barrier properties (43). This may underlie the increased albuminuria. AGE-RAGE interactions also have been shown to stimulate endocytosis and transcytosis of AGES in ECs (44), thus probably causing the abluminal accumulation of AGES, to which mural cells like mesangial cells would then be exposed. AGE-induced oxidant stress might also accelerate CML production in situ in the glomeruli (45). The exposure to AGES has been shown to be followed by the transcriptional induction of the mesangial cell synthesis of type IV collagen, a major component of the expanded ECM in diabetic nephropathy (46, 47). This induction was also proved to be mediated by RAGE (15). In addition, positive staining for type I and IV collagen was noted in the glomeruli of the present nephropathy model (data not shown). Moreover, EC expression of VCAM-1 is also known to be induced by AGE engagement of RAGE (48), enhancing mononuclear cell adhesion to the capillary wall, which would allow macrophage invasion into the mesangial area. This may provide an additional source of cytokines such as TGF-β that can contribute to the development of glomerulosclerosis. The flk-1 promoter employed to construct RAGETg in this work is known to also work in the monocyte-macrophage lineage (49). The RAGE overexpression in monocytes (Figure 1d) is considered to be consistent with this notion and may augment the interaction with AGE on invaded macrophages, thereby contributing to accelerating the progression of nephropathy in the present model.

RAGE engagement by endogenous ligands, namely amphoterin (50) and EN-RAGE (S100/calgranulins; ref. 51), is reportedly involved in the network formation of cerebral neurons and in proinflammatory reactions, respectively. The S100/calgranulins are known to be released from activated inflammatory cells, including mononuclear phagocytes as well as polymorphonuclear leukocytes and lymphocytes (52). The immuno-

fluorescence analysis of the kidney sections revealed that renal glomeruli were stained for S100/calgranulins in diabetic (DM RAGETg+ and DM RAGETg–) but not in nondiabetic (DM RAGETg+ and DM RAGETg–) groups, the heaviest stain being marked in DM RAGETg+ (data not shown). This suggests that the diabetic kidney contains two RAGE ligands, both nonenzymatically glycated adducts and S100/calgranulin proteins, and that S100/calgranulins accumulating in the kidney lesions could further activate ECs and monocytes/macrophages via their engagement of RAGE. AGES are senescent proteins that accumulate during prolonged diabetic exposure, and can also engage cell surface RAGE, this resulting in the deterioration of vascular functions (12, 15, 53). Diabetic complications appear to exploit molecular devices primarily evolved for development and survival.

Acknowledgments

The authors thank S. Matsudaaira, R. Kitamura, T. Yachi, and Y. Shichinohe for assistance, S. Kim and Y. Ouchi (University of Tokyo) for blood pressure measurement, and B. Bell for reading the manuscript. This work was supported in part by the “Research for the Future” Program of Japan Society for the Promotion of Science (grant 97L00805), by a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (no. 12770054), and by a research fund from the Hokuriku Industrial Advancement Center.


